Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo, NeoPharm, HLS Therap, CSL Behring - LARVOL DELTA

IMPLICATIONS OF THE 2026 ACC/AHA DYSLIPIDEMIA GUIDELINE FOR PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (AASLD 2026) - "In severe hypercholesterolemia, maximally tolerated statin therapy with early addition of ezetimibe, PCSK9 inhibitors, bempedoic acid and in selected cases inclisiran, is recommended to achieve target LDL-C thresholds. The 2026 ACC/AHA dyslipidemia guideline reframes lipid management as a core component of hepatology care. Its explicit endorsement of statin safety in stable liver disease, use of LDL-C goal-based intensification and incorporation of incidental CAC provide a practical framework for hepatologists to reduce cardiovascular mortality in MASLD. These updates support a more proactive heart-liver model of care and should be incorporated into hepatology clinic workflows and multidisciplinary MASLD management pathways."

Clinical • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Hepatology • Hypertriglyceridemia • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB • PCNA

Treatment patterns in homozygous familial hypercholesterolemia: Undertreatment and delayed adoption of low-density lipoprotein receptor-independent therapies. (PubMed, Am J Prev Cardiol) - "A retrospective HoFH cohort was formed using closed claims for evinacumab and lomitapide from the Komodo Healthcare Map® and confirmed diagnoses from myRARE®...At the index date, 42.8% (113/264) of individuals were dispensed LDLR-dependent LLTs only, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, and bile acid sequestrants...Over the 3 years before the index date, LDLR‑independent pharmacotherapy use increased (17.1% to 43.2%); use of LDLR-dependent LLTs decreased slightly (49.2% to 40.5%). In the United States, individuals with HoFH are currently undertreated, with significant delays in the adoption of LDLR-independent pharmacotherapies."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

Bempedoic Acid Therapy for Polycystic Kidney Disease (BEAT-PKD) Randomized Clinical Trial (KIDNEY WEEK 2026) - P2 | "In the BEAT-PKD randomized clinical trial funded by the U.S. Department of Defense, we will test whether treatment with bempedoic acid is safe and tolerable and will help reverse dysfunctional metabolism and slow disease progression in individuals with ADPKD, including those treated with tolvaptan. NCT07282821."

Clinical • Autosomal Dominant Polycystic Kidney Disease • Dyslipidemia • Genetic Disorders • Hepatology • Liver Failure • Metabolic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis. (PubMed, Endocrinol Diabetes Metab) - "Oral non-statin combination therapies, particularly obicetrapib plus ezetimibe and bempedoic acid plus ezetimibe, provide the most effective LDL-C lowering and are valuable for patients with statin intolerance or residual risk. Ezetimibe remains a well-tolerated option. Long-term cardiovascular outcome trials are needed to confirm clinical benefit."

Clinical • Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Musculoskeletal Pain • Pain • APOB

Bempedoic Acid: From Guidelines to the Real World. (PubMed, J Lipid Atheroscler) - "Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk in high- and very-high-risk individuals unable or unwilling to take statins. This updated review 1) outlines the basic pharmacology of bempedoic acid, 2) summarizes the results of clinical trials and real-world studies evaluating the efficacy and safety of bempedoic acid in the treatment of dyslipidemias, and 3) discusses the various current guidelines on the use of bempedoic acid in clinical practice."

Journal • Real-world evidence • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

LDL-C Target Attainment and Treatment Gaps Six Months After Acute Coronary Syndrome: insights from the CALLINICUS-Hellas registry. (PubMed, Hellenic J Cardiol) - "Despite progress, LDL-C target attainment after ACS remains suboptimal, largely due to clinical inertia and guideline-recommended LLT underuse. Early initiation of combination LLT after ACS could substantially improve target attainment."

Clinical • Journal • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

BEAT-PKD: Bempedoic Acid Therapy for Polycystic Kidney Disease (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Kenneth Hallows | Not yet recruiting ➔ Recruiting

Enrollment open • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Bempedoic acid attenuates glial lipid droplet accumulation and inflammatory responses and alleviates chronic social defeat stress-induced depressive-like behaviors in mice. (PubMed, Biochem Biophys Res Commun) - "Whole-brain RNA sequencing and quantitative PCR further showed changes in cytokine- and chemokine-related pathways after BPA treatment. These findings support further evaluation of BPA as a drug-repurposing candidate for stress-related depression."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mental Retardation • Mood Disorders • Psychiatry • DLG4 • GFAP

Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome. (PubMed, Int J Mol Sci) - "Management requires a multimodal approach tailored to the patient's lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • ANGPTL3 • APOB

Bempedoic acid vs ezetimibe in routine care: Observation time, residual confounding, and endpoint interpretation. (PubMed, J Clin Lipidol) - No abstract available

Journal

Case Report: Synergistic potential of RANKL and ACLY inhibition in a breast cancer patient with acquired resistance to CDK4/6 inhibitors. (PubMed, Front Oncol) - "Subsequent treatment with the CDK4/6i ribociclib in combination with fulvestrant resulted in disease progression approximately one year later, indicating acquired resistance. Due to progressive bone loss, denosumab was initiated for skeletal support, and bempedoic acid was later added for dyslipidemia...It highlights the potential need to explore biomarker-driven approaches-such as evaluating LGR4 expression to guide RANKL inhibition-to personalize treatment. Additionally, it raises the possibility that repurposed supportive care medications, such as bempedoic acid, might offer hypothetical anti-neoplastic benefits, warranting broader clinical validation to overcome complex resistance mechanisms."

Journal • Preclinical • Breast Cancer • Dyslipidemia • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Metabolic Disorders • Oncology • Solid Tumor • AMPK • ER • HER-2 • LGR4

Management of Lorlatinib-Induced Hyperlipidemia With PCSK9 Inhibitors: A Case Series (IASLC-WCLC 2026) - "Case Description : Case 1: A 66-year-old male on second-line lorlatinib 75 mg daily had normal baseline lipid levels but progressed to mixed hyperlipidemia refractory to pravastatin 40 mg daily, and partially improved on rosuvastatin 40 mg daily and ezetimibe 10 mg daily. After prolonged lifestyle modification attempts over four and a half years, alirocumab 75 mg/mL every 2 weeks (Q2W) was added, achieving lipid control (Figure 1)...She transitioned to evolocumab 140 mg/mL Q2W with bempedoic acid 180 mg daily with mild improvement...Conclusions : These four case reports illustrate the benefit of addition of a PSCK9i in treatment-related, refractory hyperlipidemia. PSCK9i are effective in lowering total cholesterol and LDL in patients with lorlatinib-induced hyperlipidemia and may be considered early in severe and statin-refractory cases."

Clinical • Dyslipidemia • Hypertension • Immunology • Lung Cancer • Mixed Hyperlipidemia • Musculoskeletal Pain • Non Small Cell Lung Cancer • Solid Tumor • ALK

Cholesterol Metabolism in Cancer Patients: Mechanisms, Treatment-Related Effects, and Cardio-Oncology Management. (PubMed, Oncol Res) - "Novel agents, including ezetimibe, bempedoic acid, and proprotein convertase subtilisin-kexin type 9 inhibitors, provide additional therapeutic options, with emerging evidence supporting their immunomodulatory and anticancer properties, especially in combination with immune checkpoint inhibitors. In addition, several anticancer therapies may profoundly affect lipid metabolism, thereby contributing to CV risk in cancer patients. The aim of this review is to provide a comprehensive overview of the interplay between cholesterol metabolism and cancer, to summarize the lipid-modifying effects of anticancer therapies, and to discuss the potential role of lipid-lowering strategies within the evolving framework of cardio-oncology care."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Oncology

A fibrosis-informed refinement of the intermediate-risk stratum for statin allocation: a liver-derived hypothesis anchored to the 2026 PREVENT-based guideline framework. (PubMed, Front Med (Lausanne)) - "I situate the framework alongside resmetirom, incretin therapy, and bempedoic acid, define the fibrosis boundary beyond which competing liver-related mortality invalidates it, and specify a competing-risks validation design aligned to the PREVENT total cardiovascular disease endpoint, externally validated in East Asian and lean-MASLD cohorts. The contribution is a fully specified, falsifiable decision architecture for the stratum where guidelines leave clinicians most uncertain."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Ezetimibe/bempedoic acid combination in statin-induced anti-HMGCR positive immune-mediated necrotizing myopathy: a case series. (PubMed, Rheumatology (Oxford)) - "EZ/BA combination therapy appears safe and effective in patients with statin-induced IMNM. However, confirmation through longer follow-up and validation in multicenter cohorts is required before recommendation as a viable alternative to statins is appropriate."

Journal • Dyslipidemia • Immunology • Metabolic Disorders • Myositis

Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study. (PubMed, Lipids Health Dis) - "Findings from this real-world, multicentre study conducted in Germany show that bempedoic acid may present an effective treatment option for patients with hypercholesterolaemia who are already receiving LLT, in addition to being an effective option for patients not receiving/tolerating other LLTs. The magnitude of LDL-C reduction differed across background treatment strategies, while suspected adverse events and treatment discontinuation were common in this specialist-care cohort."

Journal • Observational data • Real-world evidence • Retrospective data • Cardiovascular • Dyslipidemia • Mixed Hyperlipidemia • Musculoskeletal Pain • Pain

Familial Hypercholesterolemia. (PubMed, Methodist Debakey Cardiovasc J) - "Prompt recognition and treatment with statins, often combined with ezetimibe, modifies the natural course of the disease...In statin-intolerant patients, bempedoic acid may provide additional therapeutic options. The most severe form, homozygous FH (HoFH), has an estimated prevalence of ~1 in 367,000 individuals and is associated with ASCVD in youth, calcific aortic stenosis, and a markedly reduced life expectancy. Patients with HoFH require specialized care and may need LDL apheresis and specific orphan drugs such as lomitapide or evinacumab."

Biomarker • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • APOB

EFFICACY AND SAFETY OF BEMPEDOIC ACID FOR CARDIOVASCULAR RISK REDUCTION IN STATIN-INTOLERANT PATIENTS: A SYSTEMATIC REVIEW OF META-ANALYSES (CHEST 2026) - No abstract available

Clinical • Review • Cardiovascular

A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction. (PubMed, Ann Intern Med) - "For very high-risk patients with atherosclerotic cardiovascular disease, the guideline now suggests combination therapy with high-intensity or maximally tolerated statins plus ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. For statin-intolerant patients, alternatives include bempedoic acid, ezetimibe, fibrates, or PCSK9 monoclonal antibody inhibitors."

Clinical guideline • Journal • Atherosclerosis • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease

Autosomal Recessive Hypercholesterolemia Due to a Novel Homozygous LDLRAP1 Frameshift Mutation. (PubMed, JACC Case Rep) - "Early genetic diagnosis helps distinguish ARH from phenotypically similar disorders and guides treatment and counseling."

Journal • Atherosclerosis • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pain • Pediatrics

Efficacy and safety of add-on bempedoic acid on maximal dose of rosuvastatin and ezetimibe in patients with established coronary artery disease (ADDBEMPERE study). (PubMed, J Clin Lipidol) - "Addition of BA to the full dose of rosuvastatin and ezetimibe leads to a significant reduction in LDL-C. Benefits start early and are sustained. Therapy is well tolerated."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Myositis • Renal Disease • Rheumatology • CRP

Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters. (PubMed, Curr Atheroscler Rep) - "Major updates include reintroduction of goal-directed therapy, lower LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) targets, and broader use of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, bempedoic acid, and inclisiran. The guideline also emphasizes structured lipid monitoring and a systematic approach to statin-attributed muscle symptoms to reduce therapeutic inertia, preserve effective lipid-lowering therapy, and support sustained goal attainment. Collectively, these updates mark a transition toward precision lipidology, emphasizing individualized risk assessment, earlier treatment escalation, structured follow-up, preservation of effective therapy despite treatment-related symptoms, and more comprehensive reduction of residual cardiovascular risk in secondary prevention."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOB

Safety of lipid-lowering therapies: it is time for a "DOCebo" effect. (PubMed, Nutr Metab Cardiovasc Dis) - "The analysis suggests that PCSK9 monoclonal antibodies have the most favourable profile for creatine kinase elevation, new-onset diabetes and liver dysfunction, whereas bempedoic acid ranks best for myalgia risk...Clinicians should therefore promote an evidence-based "DOCebo" effect through trust, shared decision-making and clear counselling. Ultimately, safety should guide treatment personalization without displacing absolute cardiovascular benefit as the primary determinant of therapy."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Developmental Disorders • Diabetes • Hepatology • Liver Failure • Metabolic Disorders • Musculoskeletal Pain • Pain

Dyslipidaemia guideline issued by the Department of Internal Medicine (DIM) at the University Hospital Zurich (USZ) (PubMed, Praxis (Bern 1994)) - "In addition to lifestyle optimization, statins remain the first-line treatment. If the required LDL-C reduction is not achieved with statins alone, Ezetimibe, bempedoic acid, and PCSK9 inhibitors should be added sequentially."

Clinical guideline • Journal • Review • Cardiovascular • Dyslipidemia

Lipid And Anti-Inflammatory Effects Of Bempedoic Acid Across Treatment Regimens: A Harmonized Meta-Analysis Of Randomized Trials [Poster no. 695] (HFSA 2026) - No abstract available

Retrospective data